1. Summary
Advantages
- The stock's return over the last year (38.52%) is higher than the sector average (0.8288%).
- The company's current efficiency (ROE=16.26%) is higher than the sector average (ROE=11.52%)
Disadvantages
- Price (1144.21 $) is higher than fair price (370.2 $)
- Dividends (0%) are below the sector average (1.3922%).
- Current debt level 8.16% has increased over 5 years from 6.04%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
7 September 03:34 Insider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
Other news
2.3. Market efficiency
| Regeneron | Healthcare | Index | |
|---|---|---|---|
| 7 days | -0% | -14.3% | 3.7% |
| 90 days | 9.5% | -11.4% | -0.3% |
| 1 year | 38.5% | 0.8% | 27.8% |
REGN vs Sector: Regeneron has outperformed the "Healthcare" sector by 37.7% over the past year.
REGN vs Market: Regeneron has outperformed the market by 10.7% over the past year.
Stable price: REGN is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: REGN with weekly volatility of 0.7409% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (1144.21 $) is higher than the fair price (370.2 $).
Price is higher than fair: The current price (1144.21 $) is 67.6% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (24.35) is lower than that of the sector as a whole (47.98).
P/E vs Market: The company's P/E (24.35) is lower than that of the market as a whole (54.48).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.71) is lower than that of the sector as a whole (4.81).
P/BV vs Market: The company's P/BV (3.71) is higher than that of the market as a whole (2.26).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (7.34) is lower than that of the sector as a whole (33.73).
P/S vs Market: The company's P/S indicator (7.34) is lower than that of the market as a whole (9.93).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (23.78) is higher than that of the sector as a whole (-22.49).
EV/Ebitda vs Market: The company's EV/Ebitda (23.78) is higher than that of the market as a whole (22.14).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 17.26% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (17.26%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-16.46%).
5.4. ROE
ROE vs Sector: The company's ROE (16.26%) is higher than that of the sector as a whole (11.52%).
ROE vs Market: The company's ROE (16.26%) is lower than that of the market as a whole (31.72%).
5.5. ROA
ROA vs Sector: The company's ROA (12.69%) is higher than that of the sector as a whole (0.7317%).
ROA vs Market: The company's ROA (12.69%) is higher than that of the market as a whole (7.11%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (43.65%) is higher than that of the sector as a whole (7.57%).
ROIC vs Market: The company's ROIC (43.65%) is higher than that of the market as a whole (10.64%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.3922%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Оплатите подписку
Больше функциональности и данных для анализа компаний и портфеля доступно по подписке
